# This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus

> **NCT00531063** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 237 (estimated)

## Conditions studied

- Renal Transplantation

## Interventions

- **DRUG:** Everolimus (RAD001)

## Key facts

- **NCT ID:** NCT00531063
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-11
- **Primary completion:** 2005-08
- **Final completion:** —
- **Target enrollment:** 237 (ESTIMATED)
- **Last updated:** 2011-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00531063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00531063, "This is a Two-year Follow-up Study to Evaluate the Long-term Safety, Tolerability and Efficacy of 2 Different Doses of Everolimus". Retrieved via AI Analytics 2026-08-11 from https://api.ai-analytics.org/clinical/NCT00531063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*